1. Scrip
  2. >>Business

Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO

PepGen Went Public On 5 May As Well

 
• By Mandy Jackson

Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.

Finance Watch Public Company
• Source: Alamy

Bausch + Lomb, Corporation finally completed its long-anticipated split from Bausch Health Companies Inc. via an initial public offering on 5 May that grossed $630m from the sale of 35 million shares at $18 each, but Bausch Health continues to be the majority shareholder in the eye care company.

The offering priced well below the $21 to $24 range that Bausch + Lomb proposed in a 28 April filing with the US Securities and Exchange Commission (SEC), demonstrating the difficulty of the current financial markets when even one of the year’s most anticipated IPOs has a tough time launching at its preferred terms. PepGen Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.